GGT’s subordinate company, StemTech Labs, is involved in production, distribution, and research with umbilical cord and placenta-derived stem cells in Ecuador and the United States. Plans are underway to establish laboratories and treatment centers in India and Ukraine, as well as more than 25 separate stem cell laboratories in the United States.
StemTech does not do research with embryonic or fetal stem cells, and uses only the discarded “afterbirth” tissues (placenta and umbilical cord) from normal term births as the source of its stem cell products.
Stem cells have been used for treatment of many disorders, and the 70 diseases successfully treated include stroke, brain trauma, cerebral palsy, multiple sclerosis, rheumatoid arthritis, liver cirrhosis, diabetes, and spinal cord injuries.
StemTech Labs is interested in partnering with other innovative individuals in establishing stem cell production labs, research labs, and treatment centers. We are also interested in providing stem cell products to physicians for treatment of their own patients.
.
